Basit öğe kaydını göster

dc.contributor.authorHacıoğlu, Muhammet Bekir
dc.contributor.authorKöstek, Osman
dc.contributor.authorKurt, Nazmi
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorGökyer, Ali
dc.contributor.authorUstabaşıoğlu, Fethi Emre
dc.contributor.authorKarataş, Fatih
dc.contributor.authorTunçbilek, Nermin
dc.contributor.authorUzunoǧlu, Sernaz
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorErdoğan, Bülent
dc.date.accessioned2019-12-27T17:21:14Z
dc.date.available2019-12-27T17:21:14Z
dc.date.issued2019en_US
dc.identifier.citationHacıoğlu, M. B., Köstek, O., Kurt, N., Küçükarda, A., Gökyer, A., Ustabaşıoğlu, F. E. ... Erdoğan, B. (2019). Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102. Journal of B.U.ON., 24(5), 2198-2204.en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4786
dc.description.abstractPurpose: To assess whether regorafenib and TAS-102 treatments are associated with a change in Skeletal Muscle Area (SMA) as well as to compare Skeletal Muscle Mass (SMM) loss levels between regorafenib and TAS-102 treatments and prognostic significance in the patients with metastatic colorectal cancer (mCRC). Methods: A total of 36 mCRC patients, who received regorafenib or TAS-102 in the third-line and subsequent settings were assessed in the analysis. SMM changes were assessed with CT scans findings, and they were categorized into two groups as SMM-loss (SMM decrease ≥2%) and SMM-stable (SMM change <2%). Results: The SMM change after regorafenib therapy was significantly worse compared with TAS-102 therapy (p=0.001). The median overall survival (OS) was longer in SMM-stable group than in SMM-loss group (12.8 months; 95%CI:9.8-15.7) vs. 6.4 months; 95%CI:5.2-7.7, respectively;p=0.04). Cox regression analysis showed that SMM loss was independent prognostic indicator for OS (HR, 2.87; 95%CI: 1.07-7.42, p=0.03). Conclusion: Although patients who received regorafenib had more SMM loss than those who received TAS-102, there was no difference in OS between drugs.en_US
dc.language.isoengen_US
dc.publisherZerbinis Publicationsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectRegorafeniben_US
dc.subjectTAS- 102en_US
dc.subjectSarcopeniaen_US
dc.subjectSkeletal Muscle Massen_US
dc.titleComparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102en_US
dc.typearticleen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.authorid0000-0001-9717-4581en_US
dc.identifier.volume24en_US
dc.identifier.issue5en_US
dc.identifier.startpage2198en_US
dc.identifier.endpage2204en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.wosqualityQ4en_US
dc.identifier.scopusqualityQ3en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess